GOLDMAN SACHS GROUP INC - GRACELL BIOTECHNOLOGIES INC ownership

GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 33 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of GRACELL BIOTECHNOLOGIES INC
ValueSharesWeighting
Q3 2023$46,022
-30.0%
15,980
-7.4%
0.00%
Q2 2023$65,738
+102.3%
17,254
-1.2%
0.00%
Q1 2023$32,492
-31.0%
17,469
-14.6%
0.00%
Q4 2022$47,060
-37.3%
20,461
-12.3%
0.00%
Q3 2022$75,000
-44.0%
23,319
-4.0%
0.00%
Q2 2022$134,000
-44.9%
24,278
-76.7%
0.00%
Q1 2022$243,000
+125.0%
104,419
+482.7%
0.00%
Q4 2021$108,00017,9190.00%
Other shareholders
GRACELL BIOTECHNOLOGIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 3,445,973$8,029,0000.68%
Paradigm Biocapital Advisors LP 783,445$1,825,0000.48%
Orbimed Advisors 7,884,870$18,372,0000.30%
Vivo Capital, LLC 961,359$2,240,0000.15%
EcoR1 Capital, LLC 1,559,710$3,634,0000.11%
Temasek Holdings (Private) Ltd 9,901,940$23,071,5200.10%
Capital International, Inc./CA/ 2,335,476$5,442,0000.06%
Virtus ETF Advisers LLC 24,728$58,0000.03%
Capital International Sarl 228,149$532,0000.03%
FEDERATED HERMES, INC. 1,298,578$3,026,0000.01%
View complete list of GRACELL BIOTECHNOLOGIES INC shareholders